2seventy bio (NASDAQ:TSVT) Earns “Outperform” Rating from Wedbush

Wedbush reissued their outperform rating on shares of 2seventy bio (NASDAQ:TSVT – Free Report) in a research note published on Tuesday, RTT News reports. The brokerage currently has a $4.00 target price on the stock, down from their previous target price of $7.00. Wedbush also issued estimates for 2seventy bio’s Q4 2023 earnings at ($0.91) […]

Leave a Reply

Your email address will not be published.

Previous post Orioles sign Jorge Mateo, 3 others to 2024 deals, tender contracts to remaining 13 arbitration-eligible players
Next post StockNews.com Begins Coverage on Tenax Therapeutics (NASDAQ:TENX)